SEC EDGARSEP 41 min read$VCYT

McGuire Annie sold $140K of VCYT

McGuire Annie (EVP, General Counsel) sold 3,254 shares of VERACYTE, INC. (VCYT) at an average of $43.09 ($42.79–$43.67, $0.14M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · McGuire Annie

Published Sep 4, 2026, 11:54 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 11:58 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$VCYT

Neutral

medium confidence

Mentioned

$VCYT

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$VCYTNeutralLow

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited trading insight.

Market read

Minor insider sell; unlikely to affect market perception or price.

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 3/10Novelty 4/10Timing: same-day filing 2026-09-04

Background

Form 4 filings disclose insider trades; VCYT is a Nasdaq-listed molecular diagnostics company.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$VCYTNeutralMedium confidence

Context

Officer sold $140K of shares via 10b5-1 plan, reducing holdings to 131,160 shares.

Expected impact

minimal short-term price pressure, likely within normal volatility.

Evidence & confidence

Sale size is small relative to market cap; typical for 10b5-1 plans, unlikely to move price materially.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

Limited to US biotech market, negligible.

Global

None.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

Company
Veracyte, Inc.
NASDAQ-listed molecular diagnostics firm.
Insider
Annie McGuire
Executive Vice President, General Counsel.

Read at source ← All news

OCT 23

$VCYTMedAI 8/10

Veracyte, Inc. (VCYT) Decipher Test Shown to Predict Abiraterone Benefit in Very High-Risk Prostate Cancer

Veracyte reported that its Decipher Prostate test can predict which very high-risk nonmetastatic prostate cancer patients may benefit from adding abiraterone to ADT, based on a retrospective Phase III STAMPEDE analysis. The test's evidence base now extends to predicting treatment benefit, not just risk stratification.

tradingview.com2 min

OCT 23

$VCYTMedAI 8/10

An 11% five-year benefit against prostate cancer spread came with added treatment for men with very high test scores.

Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.

stocktitan.net2 min

OCT 16

$VCYTMed

Veracyte, Inc. (VCYT) Wins Medicare Coverage for Prosigna Test

Veracyte (VCYT) announced Medicare coverage for its Prosigna Breast Cancer test, effective August 19, 2026, for eligible patients. The decision marks an early commercialization milestone, according to the company.

tradingview.com1 min

OCT 16

$VCYTMed

A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients

Veracyte's Prosigna test for early-stage breast cancer received Medicare coverage, enabling reimbursement for eligible patients. The test helps determine chemotherapy necessity, sparing over two-thirds of high-risk patients, per the OPTIMA trial. Veracyte (VCYT) aims for broader adoption and access.

stocktitan.net2 min

SEP 14

$VCYTHigh

VERACYTE, INC. (VCYT): Completion of Acquisition or Disposition of Assets

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the

SEC EDGAR 8-K2 min

JUL 30